IL304365B2 - A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereof - Google Patents
A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereofInfo
- Publication number
- IL304365B2 IL304365B2 IL304365A IL30436523A IL304365B2 IL 304365 B2 IL304365 B2 IL 304365B2 IL 304365 A IL304365 A IL 304365A IL 30436523 A IL30436523 A IL 30436523A IL 304365 B2 IL304365 B2 IL 304365B2
- Authority
- IL
- Israel
- Prior art keywords
- interleukin
- analog
- amino acid
- amino acids
- long
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20210042305 | 2021-03-31 | ||
| PCT/KR2022/004620 WO2022211537A1 (ko) | 2021-03-31 | 2022-03-31 | 신규한 면역 활성 인터루킨 2 아날로그 결합체 및 이의 제조 방법 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL304365A IL304365A (en) | 2023-09-01 |
| IL304365B1 IL304365B1 (en) | 2024-12-01 |
| IL304365B2 true IL304365B2 (en) | 2025-04-01 |
Family
ID=83459706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL304365A IL304365B2 (en) | 2021-03-31 | 2022-03-30 | A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereof |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US12599675B2 (https=) |
| EP (1) | EP4316528A4 (https=) |
| JP (1) | JP2024512418A (https=) |
| KR (2) | KR102680146B1 (https=) |
| CN (1) | CN116916969A (https=) |
| AR (1) | AR125263A1 (https=) |
| AU (1) | AU2022209248B2 (https=) |
| BR (1) | BR112023018530A2 (https=) |
| CA (1) | CA3205058C (https=) |
| CL (1) | CL2023002504A1 (https=) |
| IL (1) | IL304365B2 (https=) |
| MX (1) | MX2023010926A (https=) |
| PE (1) | PE20250672A1 (https=) |
| WO (1) | WO2022211537A1 (https=) |
| ZA (1) | ZA202307219B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022009123A1 (en) * | 2020-07-09 | 2022-01-13 | Eutilex Co., Ltd. | Il-2 variants |
| AU2023408268A1 (en) | 2022-12-23 | 2025-07-10 | Hanmi Pharm. Co., Ltd. | Formulations comprising immune stimulating IL-2 analog conjugates |
| KR20240137492A (ko) * | 2023-03-07 | 2024-09-20 | 한미약품 주식회사 | 암의 예방 또는 치료를 위한 인터루킨 2 아날로그 또는 이의 결합체 및 면역관문 억제제의 병용 요법 |
| JP2026509259A (ja) * | 2023-03-07 | 2026-03-17 | ハンミ ファーマシューティカル カンパニー リミテッド | インターロイキン２アナログ又はその結合体を含む癌予防又は治療用薬学的組成物 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018089420A1 (en) * | 2016-11-08 | 2018-05-17 | Delinia, Inc. | Il-2 variants for the treatment of autoimmune diseases |
| KR20200078312A (ko) * | 2018-12-21 | 2020-07-01 | 한미약품 주식회사 | 신규 면역 억제 인터루킨 2 (Interleukin 2) 아날로그 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| KR100507796B1 (ko) * | 2003-04-03 | 2005-08-17 | 한미약품 주식회사 | 생체내 반감기가 증가된 ｐｅｇ-생리활성 폴리펩티드 동종이량체 결합체 및 이의 제조방법 |
| HUE029139T2 (hu) * | 2011-02-10 | 2017-02-28 | Roche Glycart Ag | Mutáns interleukin-2 polipeptidek |
| MX385194B (es) * | 2014-02-21 | 2025-03-14 | Nektar Therapeutics India Pvt Ltd | Agonistas il-2rbeta-selectivos en combinación con un anticuerpo anti-ctla-4 o un anticuerpo anti-pd-1. |
| GB2538666A (en) | 2014-07-21 | 2016-11-23 | Delinia Inc | Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases |
| EP3943101A1 (en) | 2014-10-21 | 2022-01-26 | SciClone Pharmaceuticals International Ltd. | Treatment of cancer with immune stimulator alpha thymosin peptide |
| WO2017052329A1 (en) * | 2015-09-24 | 2017-03-30 | Hanmi Pharm. Co., Ltd. | Protein complex by use of a specific site of an immunoglobulin fragment for linkage |
| KR102687530B1 (ko) | 2016-05-04 | 2024-07-25 | 암젠 인크 | T-조절 세포의 증식을 위한 인터류킨-2 뮤테인 |
| MX386014B (es) * | 2016-08-10 | 2025-03-18 | Univ Ajou Ind Academic Coop Found | Citocina fusionada a fc heterodimérico, y composición farmacéutica que comprende la misma. |
| US20200299349A1 (en) * | 2017-11-21 | 2020-09-24 | The Board Of Trustees Of The Leland Stanford Junior University | Partial agonists of interleukin-2 |
| WO2019185705A1 (en) * | 2018-03-28 | 2019-10-03 | Ascendis Pharma A/S | Il-2 conjugates |
| MX2021000801A (es) * | 2018-07-24 | 2021-04-12 | BioNTech SE | Agonistas de il2. |
| WO2020057646A1 (zh) * | 2018-09-21 | 2020-03-26 | 信达生物制药(苏州)有限公司 | 新型白介素2及其用途 |
| TW202115105A (zh) | 2019-06-24 | 2021-04-16 | 德商拜恩迪克Ｒｎａ製藥有限公司 | Ｉｌ２激動劑 |
| KR20220044534A (ko) * | 2019-08-13 | 2022-04-08 | 엘피스 바이오파마슈티컬즈 | 조작된 인터류킨-2 수용체 베타 효능제 |
-
2022
- 2022-03-30 IL IL304365A patent/IL304365B2/en unknown
- 2022-03-31 EP EP22781656.8A patent/EP4316528A4/en active Pending
- 2022-03-31 BR BR112023018530A patent/BR112023018530A2/pt unknown
- 2022-03-31 AU AU2022209248A patent/AU2022209248B2/en active Active
- 2022-03-31 AR ARP220100795A patent/AR125263A1/es unknown
- 2022-03-31 KR KR1020220040626A patent/KR102680146B1/ko active Active
- 2022-03-31 US US18/000,096 patent/US12599675B2/en active Active
- 2022-03-31 PE PE2023002484A patent/PE20250672A1/es unknown
- 2022-03-31 MX MX2023010926A patent/MX2023010926A/es unknown
- 2022-03-31 WO PCT/KR2022/004620 patent/WO2022211537A1/ko not_active Ceased
- 2022-03-31 CN CN202280017977.7A patent/CN116916969A/zh active Pending
- 2022-03-31 JP JP2023555563A patent/JP2024512418A/ja active Pending
- 2022-03-31 CA CA3205058A patent/CA3205058C/en active Active
-
2023
- 2023-07-19 ZA ZA2023/07219A patent/ZA202307219B/en unknown
- 2023-08-24 CL CL2023002504A patent/CL2023002504A1/es unknown
-
2024
- 2024-06-14 KR KR1020240077657A patent/KR20240099117A/ko active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018089420A1 (en) * | 2016-11-08 | 2018-05-17 | Delinia, Inc. | Il-2 variants for the treatment of autoimmune diseases |
| KR20200078312A (ko) * | 2018-12-21 | 2020-07-01 | 한미약품 주식회사 | 신규 면역 억제 인터루킨 2 (Interleukin 2) 아날로그 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3205058C (en) | 2024-04-09 |
| ZA202307219B (en) | 2024-10-30 |
| PE20250672A1 (es) | 2025-03-04 |
| KR20240099117A (ko) | 2024-06-28 |
| EP4316528A4 (en) | 2026-03-11 |
| CA3205058A1 (en) | 2022-10-26 |
| AU2022209248B2 (en) | 2023-06-29 |
| CN116916969A (zh) | 2023-10-20 |
| US20240009317A1 (en) | 2024-01-11 |
| AR125263A1 (es) | 2023-06-28 |
| EP4316528A1 (en) | 2024-02-07 |
| CL2023002504A1 (es) | 2024-01-26 |
| KR20220136285A (ko) | 2022-10-07 |
| IL304365A (en) | 2023-09-01 |
| AU2022209248A1 (en) | 2022-10-20 |
| IL304365B1 (en) | 2024-12-01 |
| MX2023010926A (es) | 2023-09-27 |
| JP2024512418A (ja) | 2024-03-19 |
| KR102680146B1 (ko) | 2024-07-04 |
| WO2022211537A1 (ko) | 2022-10-06 |
| US12599675B2 (en) | 2026-04-14 |
| BR112023018530A2 (pt) | 2023-10-10 |
| TW202304521A (zh) | 2023-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12599675B2 (en) | Conjugate of immune-stimulating il-2 analog and preparation method thereof | |
| JP7415047B2 (ja) | インターロイキン－２受容体βγｃ二量体について偏向され、非ペプチド性水溶性ポリマーにコンジュゲートされたヒトインターロイキン－２コンジュゲート | |
| KR102946368B1 (ko) | 신규한 면역 활성 인터루킨 2 아날로그 | |
| EP3896085A1 (en) | Anti-human interleukin 5(il-5) monoclonal antibody and use thereof | |
| TW201927806A (zh) | Ｇｌｐ－２衍生物之長效接合物 | |
| CN111944036A (zh) | 一种增殖免疫细胞的突变体蛋白 | |
| KR20220092442A (ko) | 신규한 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중활성체 및 이의 용도 | |
| JP2023538236A (ja) | グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに対して活性を有する三重活性体を含む血圧降下用薬学組成物 | |
| CN110536899A (zh) | 对胰岛素受体具有降低的亲和力的胰岛素类似物复合物及其用途 | |
| HK40100172A (en) | Novel immunoactive interleukin 2 analog conjugate and method for preparing same | |
| EP4678180A1 (en) | Pharmaceutical composition for preventing or treating cancer including interleukin 2 analog or conjugate thereof | |
| EP4678181A1 (en) | Combination therapy of interleukin-2 analog or conjugate thereof and immune checkpoint inhibitor for prevention or treatment of cancer | |
| EA049515B1 (ru) | Новый конъюгат иммуностимулирующего аналога интерлейкина-2 и способ его получения | |
| HK40130618A (en) | Combination therapy of interleukin-2 analog or conjugate thereof and immune checkpoint inhibitor for prevention or treatment of cancer | |
| KR20220041766A (ko) | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체의 다발성 경화증의 치료 용도 | |
| KR20230149258A (ko) | 장질환의 예방 또는 치료를 위한 GLP-2와, 인슐린 분비 펩타이드, TNFα 억제제, 또는 이 둘 모두의 병용 요법 | |
| KR20240102886A (ko) | 면역 활성 인터루킨 2 아날로그 결합체를 포함하는 제제 |